The Structure of Concomitant Pathology in Patients With Hypertrophic Cardiomyopathy in The Older Age Group. Review and Clinical Observations

Advances in modern drug and surgical treatment of patients with hypertrophic cardiomyopathy (HCM) have resulted in a significant increase in the life expectancy of these extremely severe patients. Therefore, in addition to the genetic markers, major neurohumoral systems and morpho-functional parameters of intracardiac hemodynamics, the course and prognosis of the disease are influenced by concomitant pathology. In infancy and early childhood, HCM is associated with tumors of chromaffin tissue of various localizations; however, the older the patient, the greater the likelihood of developing metabolic syndrome, secondary atherosclerosis and ischemic heart disease (IHD), and hypertension, which significantly complicates the verification of the HCM diagnosis. We have previously described cases of IHD secondary to HCM, which significantly affected the course and prognosis of both diseases. However, in old age, other comorbidities may also occur in addition to the diseases described above. Based on long-term observation of a large cohort of patients, this article analyzes a wide range of HCM combinations with pathology of other organs and systems, including malignant neoplasms, which makes significant adjustments to the treatment of both the underlying disease and cancer. The material is presented in the form of a brief review of literature on this topic and our own clinical observations and studies.

1. Kwok SY, Cheng FWT, Lo AFC, Leung WK, Yam MC, Li CK. Variants of Cardiomyopathy and Hypertension in Neuroblastoma. Journal of Pediatric Hematology/Oncology. 2014;36(3):e158–61. DOI: 10.1097/MPH.0b013e318290c628

2. Hauser J, Riedl S, Michel-Behnke I, Minkov M, Perneczky E, Horcher E. Hypertrophic Obstructive Cardiomyopathy in an Infant With an Adrenocortical Tumor. Pediatrics. 2013;132(2):e535–9. DOI: 10.1542/peds.2012-2692

3. Zhang R, Gupta D, Albert SG. Pheochromocytoma as a reversible cause of cardiomyopathy: Analysis and review of the literature. International Journal of Cardiology. 2017;249:319–23. DOI: 10.1016/j.ijcard.2017.07.014

4. Olmati F, Petramala L, Bisogni V, Concistré A, Saracino V, Oliviero G et al. A rare case report of hypertrophic cardiomyopathy induced by catecholamine-producing tumor. Medicine. 2018;97(50):e13369. DOI: 10.1097/MD.0000000000013369

5. Kumar A, Pappachan JM, Fernandez CJ. Catecholamine-induced cardiomyopathy: an endocrinologist’s perspective. Reviews in Cardiovascular Medicine. 2021;22(4):1215–28. DOI: 10.31083/j.rcm2204130

6. Betancur JF, Adams-Sánchez C, Restrepo-Giraldo L, Arévalo-Novoa J, Ramírez B, Llano JF et al. Hypertrophic cardiomyopathy in a patient with secondary hypoparathyroidism: A case report. Radiology Case Reports. 2022;17(12):4589–93. DOI: 10.1016/j.radcr.2022.08.092

7. Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C et al. Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy. Cell Metabolism. 2015;22(6):1020–32. DOI: 10.1016/j.cmet.2015.09.002

8. Liu L, Shen L, Liu S, Tu B, Li G, Hu F et al. Correlations between low thyroid function and incidence of atrial fibrillation in hypertrophic obstructive cardiomyopathy. Chronic Diseases and Translational Medicine. 2020;6(1):35–45. DOI: 10.1016/j.cdtm.2020.02.002

9. He C, Zhu C, Fan H, Qian Y, Zhai C, Hu H. Low T3 syndrome predicts more adverse events in patients with hypertrophic cardiomyopathy. Clinical Cardiology. 2023;46(12):1569–77. DOI: 10.1002/clc.24156

10. Sun J, Liu X, Zhang Q, Hong Y, Song B, Teng X et al. Papillary Thyroid Carcinoma Treated with Radiofrequency Ablation in a Patient with Hypertrophic Cardiomyopathy: A Case Report. Korean Journal of Radiology. 2016;17(4):558–61. DOI: 10.3348/kjr.2016.17.4.558

11. Zhou H, Lei X, Yan Y, Lydic T, Li J, Weintraub NL et al. Targeting ATGL to rescue BSCL2 lipodystrophy and its associated cardiomyopathy. JCI Insight. 2019;4(14):e129781. DOI: 10.1172/jci.insight.129781

12. Kaplunova V.Yu., Shakaryants G.A., Kozhevnikova M.V., Ilgisonis I.S., Privalova E.V., Khabarova N.V. et al. Hypertrophic Cardiomyopathy and Ischemic Heart Disease. Variants of Combination Pathology. Kardiologiia. 2017;57(12):16–24. DOI: 10.18087/cardio.2017.12.10062

13. Belenkov Yu.N., Privalova E.V., Kaplunova V.Yu., Chekneva I.S., Najmann Yu.I., Kozhevnikova M.V. et al. Hypertrophic Cardiomyopathy and Connective Tissue Dysplasia Syndrome: Comorbidity Variants. Rational Pharmacotherapy in Cardiology. 2016;12(5):522–7. DOI: 10.20996/1819-6446-2016-12-5-522-527

14. Lupsa BC, Sachdev V, Lungu AO, Rosing DR, Gorden P. Cardiomyopathy in Congenital and Acquired Generalized Lipodystrophy: A Clinical Assessment. Medicine. 2010;89(4):245–50. DOI: 10.1097/MD.0b013e3181e9442f